The MedTech 50 celebrates businesses helping to diagnose and treat conditions, mainly in a clinical setting such as a hospital, and other biotechnology companies. We are excited to be ranked #12 by BusinessCloud.

When speaking to our patient advisors, we make sure to collect their feedback as well as record all observations we notice when they show us how they go about using certain features in the app. Check out how Jill helped us with this.

We are so excited to be the winner of the THE EUROPAS 2021 in the Hottest HealthTech Startup category! Click through to watch the virtual ceremony 📺

Vinehealth are featured in Pf magazine as a startup to watch among solutions that change behaviours transforming lives. Click through to read more.

We are excited to be shortlisted among 109 other startups and companies for MedTech 50 innovators by Business Cloud.

Cast your vote now!

We are excited to be shortlisted for the Best Innovation in Genetics and Personalised medicine award by CogX. Click through to read more details and see other candidates.

Vinehealth takes great pride in ensuring our app is accessible to all, we are always working to improve by adding thoughtful features and designs. 27% of the Vinehealth users are over 55 years old. Read more about how we made sure the app is fully accessible to them, alongside other age groups.

When speaking to our patient advisors, we make sure to collect their feedback as well as record all observations we notice when they show us how they go about using certain features in the app. Read more to learn how James helped us with this.

Vinehealth has received a Class 1 Medical Device CE mark for its Vinehealth mobile app for cancer patients and VinehealthPRO web application for clinicians.

Vinehealth conforms to the requirements of the Medical Devices Directive 93/42/EEC. The Directive outlines safety and performance requirements for medical devices in the UK & EU.

Vinehealth is delighted to announce their partnership with the University of Surrey in securing a £1 million Innovate UK grant to undertake a randomised controlled trial of our cancer companion app.